Skip to main content
SpringerLink
Log in

Post San Antonio: immunotherapy, chemotherapy and new combinations

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

This article gives a summary of several studies presented at the San Antonio Breast Cancer Symposium in 2018. In specific, the biomarker analysis of the ‘IMpassion130’ trial, the effects of CDK4/6 inhibitors on T-cells and tumor immunogenicity, adjuvant chemotherapy in older patients, the prognostic relevance of achieving a pathologic complete response after neoadjuvant therapy, the quality of life analysis of the ‘TAILORx’ trial, the prognostic impact of detecting bone marrow tumor cells at the time of primary resection and b-cell lymphoma 2 as a new possible therapeutic target in luminal breast cancer, are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Emens LA, et al. IMpassion130. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Abstract GS1-04.

    Google Scholar 

  2. Hurvitz S, et al. Abstract PD2-10: Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer. In: Poster Discussion Abstracts . American Association for Cancer Research; 2019. S. PD2-10-PD2-10.

  3. Tolaney SM, et al. Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab. J Clin Oncol. 2018;36(15_suppl):1059.

    Article  Google Scholar 

  4. Sinha S, et al. Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS2-02.

    Google Scholar 

  5. Hurria A, et al. Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS6-04.

    Google Scholar 

  6. Spring LM, et al. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS2-03.

    Google Scholar 

  7. Geyer CE Jr., et al. Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Primary results from KATHERINE. Abstract GS1-10.

    Google Scholar 

  8. Martín M, et al. Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS2-04.

    Google Scholar 

  9. Wagner LI, et al. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS6-03.

    Google Scholar 

  10. Hartkopf AD, et al. International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study. San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract GS5-07.

    Google Scholar 

  11. Lindeman GJ, et al. A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2—positive metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium; 4.–8. 12. 2018; San Antonio. 2018. Abstract PD1-06.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Vienna, Austria

    Karl Mayrhofer MD & Kathrin Strasser-Weippl MD, MBA

Authors
  1. Karl Mayrhofer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathrin Strasser-Weippl MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Mayrhofer MD.

Ethics declarations

Conflict of interest

K. Mayrhofer and K. Strasser-Weippl declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mayrhofer, K., Strasser-Weippl, K. Post San Antonio: immunotherapy, chemotherapy and new combinations. memo 12, 261–264 (2019). https://doi.org/10.1007/s12254-019-0509-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-019-0509-2

Keywords

Search

Navigation